{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=91", "query": { "condition": "Ovarian Tumors", "page": 91 }, "page_size": 10 }, "pagination": { "page": 91, "page_size": 10, "total_count": 2465, "total_pages": 247, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=92&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=90&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T07:00:58.854Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06028932", "title": "A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Carcinoma" ], "interventions": [ { "name": "Sacituzumab govitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2024-01-08", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06028932" }, { "nct_id": "NCT03030287", "title": "A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer Ovaries", "Cancer Peritoneal", "Cancer, Fallopian Tube" ], "interventions": [ { "name": "OMP-305B83", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 44, "start_date": "2016-12", "completion_date": "2020-04", "has_results": false, "last_update_posted_date": "2020-09-03", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 7, "location_summary": "Aurora, Colorado • Tampa, Florida • Charlotte, North Carolina + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03030287" }, { "nct_id": "NCT03585764", "title": "MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "MOv19-BBz CAR T cells", "type": "DRUG" }, { "name": "Alpha Folate Receptor expression test", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 46, "start_date": "2018-10-24", "completion_date": "2024-03-26", "has_results": true, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03585764" }, { "nct_id": "NCT00281632", "title": "A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peritoneal Cancer", "Ovarian Cancer", "Neoplasms, Ovarian", "Fallopian Tube Cancer" ], "interventions": [ { "name": "GW786034", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2006-03", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2018-09-17", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Austin, Texas • Bedford, Texas + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Austin", "state": "Texas" }, { "city": "Bedford", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00281632" }, { "nct_id": "NCT04487405", "title": "A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adnexal Mass" ], "interventions": [ { "name": "OVAnex", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Aspira Women's Health", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 721, "start_date": "2020-06-25", "completion_date": "2023-12-15", "has_results": false, "last_update_posted_date": "2023-12-26", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 9, "location_summary": "Chandler, Arizona • Lake Worth, Florida • Columbus, Georgia + 5 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Lake Worth", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Eden Prairie", "state": "Minnesota" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04487405" }, { "nct_id": "NCT03992131", "title": "A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Triple-negative Breast Cancer", "Urothelial Carcinoma", "Solid Tumor" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" }, { "name": "Lucitanib", "type": "DRUG" }, { "name": "Sacituzumab govitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "pharmaand GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2019-06-28", "completion_date": "2022-04-22", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03992131" }, { "nct_id": "NCT03565445", "title": "A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASP1948", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2018-07-02", "completion_date": "2023-03-27", "has_results": false, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 17, "location_summary": "New Haven, Connecticut • Louisville, Kentucky • Baltimore, Maryland + 13 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03565445" }, { "nct_id": "NCT03604653", "title": "Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stomach Cancer", "Colorectal Cancer", "Appendiceal Cancer", "Ovarian Cancer", "Uterine Cancer", "Cervical Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "HIPEC", "type": "DEVICE" }, { "name": "Mitomycin c", "type": "DRUG" }, { "name": "CDDP 50", "type": "DRUG" }, { "name": "CDDP 75", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Holy Name Medical Center, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2018-05-15", "completion_date": "2021-05-01", "has_results": false, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 1, "location_summary": "Teaneck, New Jersey", "locations": [ { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03604653" }, { "nct_id": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Gastric Cancer", "Esophageal Cancer", "Gastroesophageal Cancer", "Colorectal Cancer", "Endometrial Cancer", "Non-small Cell Lung Cancer", "Ovarian Cancer", "Urothelial Carcinoma", "Salivary Gland Cancer", "Pancreatic Cancer", "HER-2 Protein Overexpression" ], "interventions": [ { "name": "Zanidatamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-01-14", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 17, "location_summary": "Prescott, Arizona • Littleton, Colorado • Fort Myers, Florida + 14 more", "locations": [ { "city": "Prescott", "state": "Arizona" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06695845" }, { "nct_id": "NCT00038428", "title": "Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "TLK286", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2001-06", "completion_date": "2005-07", "has_results": false, "last_update_posted_date": "2011-07-25", "last_synced_at": "2026-11-02T07:00:58.854Z", "location_count": 3, "location_summary": "Los Angeles, California • New York, New York • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038428" } ] }